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Fungal, bacterial, and cancer cells can develop resistance against antifungal, antibacterial, or
anticancer agents. Mechanisms of resistance are complex and often multifactorial. Mech-
anisms include: (1) Activation of ATP-binding cassette (ABC) transporters, such as P-gp,
which pump out lipophilic compounds that have entered a cell, (2) Activation of cytochrome
p450 oxidases which can oxidize lipophilic agents to make them more hydrophilic and
accessible for conjugation reaction with glucuronic acid, sulfate, or amino acids, and (3)
Activation of glutathione transferase, which can conjugate xenobiotics.This review summa-
rizes the evidence that secondary metabolites (SM) of plants, such as alkaloids, phenolics,
and terpenoids can interfere with ABC transporters in cancer cells, parasites, bacteria,
and fungi. Among the active natural products several lipophilic terpenoids [monoterpenes,
diterpenes, triterpenes (including saponins), steroids (including cardiac glycosides), and
tetraterpenes] but also some alkaloids (isoquinoline, protoberberine, quinoline, indole,
monoterpene indole, and steroidal alkaloids) function probably as competitive inhibitors
of P-gp, multiple resistance-associated protein 1, and Breast cancer resistance protein
in cancer cells, or efﬂux pumps in bacteria (NorA) and fungi. More polar phenolics (phe-
nolic acids, ﬂavonoids, catechins, chalcones, xanthones, stilbenes, anthocyanins, tannins,
anthraquinones, and naphthoquinones) directly inhibit proteins forming several hydrogen
and ionic bonds and thus disturbing the 3D structure of the transporters. The natural prod-
ucts may be interesting in medicine or agriculture as they can enhance the activity of active
chemotherapeutics or pesticides or even reverse multidrug resistance, at least partially, of
adapted and resistant cells. If these SM are applied in combination with a cytotoxic or
antimicrobial agent, they may reverse resistance in a synergistic fashion.
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INTRODUCTION
EVOLUTIONARY AND ECOLOGICAL BACKGROUND
Plants are sessile organisms which cannot run away when attacked
by an herbivore nor do they have an immune system to combat
infesting parasites, bacteria, fungi, or viruses. From early days of
the evolution of land plants they had to cope with these envi-
ronmental challenges. Plants developed a number of mechanical
traits, such as resistant epidermal and bark tissues but also spines
and thorns as defense tools. In addition, plants evolved a high
diversity of defense chemicals, the so-called secondary metabo-
lites (SM; Table 1). Besides defense, some SM function as signal
compounds or protect against oxidative or UV stress (Wink, 1988,
2003, 2008b, 2010a,b).
The structures of SM have been optimized during evolution
in such a way that they can interfere with molecular targets
Abbreviations: ABC, ATP-binding cassette; BCRP, breast cancer resistance protein;
MDR, multidrug resistance; MRP1, multidrug resistance-associate protein; P-gp,
P-glycoprotein.
in herbivores and microbes. The main group of targets include
(1) proteins, (2) DNA, RNA, and (3) the biomembrane (Wink,
2008a,b; Wink and Schimmer, 2010). Neuronal signal transduc-
tion is a central and speciﬁc target in animals and many SM,
especially alkaloids and amines are directed toward it (Wink,
1993, 2000). SM which interfere with proteins, such as polyphe-
nols,biomembranes (saponins andother lipophilic terpenoids),or
DNA (alkylating or intercalating mutagens) affect a wider range
of organisms, including animals and microbes. In general, mem-
brane and DNA active SM have cytotoxic properties. Affected cells
usually undergo apoptosis (Wink, 2007). Several SM interfere with
the neuronal signal transduction in animals and are thus potent
neurotoxins (Wink, 1993, 2000).
A large number of SM have lipophilic properties which enable
them to readily pass biomembranes in target organisms by simple
diffusion. These SM are also dangerous for the producing plants.
Therefore, they are usually stored in dead tissue away from living
cells, such as resin ducts, oil cells, trichomes, or cuticles (Wink,
2010b). The absorption of polar SM is usually slower or does not
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Table 1 | Structural types of secondary metabolites and known
structures.
Class Number of structures
WITH NITROGEN
Alkaloids 21000







Monoterpenes (incl. iridoids) 2500
Sesquiterpenes 5000
Diterpenes 2500








Polyacetylenes, fatty acids, waxes 1500
Polyketides (quinones, anthraquinones) 750
Carbohydrates, organic acids 400
take place at all, with the exception of SM that can use transporters
for sugars or amino acids or endocytosis as a kind of “stowaway.”
Furthermore, SM usually occur in complex mixtures which may
contain SM (such as saponins) that can facilitate the uptake of
polar SM (Hebestreit and Melzig, 2003).
THE RESPONSE OF HERBIVORES AND PATHOGENS AGAINST PLANT
DEFENSE CHEMICALS
In the evolutionary arms race herbivores and microbes evolved
mechanisms to avoid or inactivate the defense chemistry of plants.
Mechanisms of resistance in animals and humans are complex and
often multifactorial. Mechanisms include: (1) Activation of ATP-
binding cassette (ABC) transporters, such as p-gp, which pump
out lipophilic compounds that have entered a cell, (2) activation
of cytochrome p450 oxidases (CYP) which can oxidize lipophilic
agents to make them more hydrophilic and accessible for conju-
gation reaction with glucuronic acid, sulfate, or amino acids, and
(3) activation of glutathione transferase (GST), which can conju-
gate xenobiotics with glutathione. The reactions of CYP, GST, and
conjugation are well known in pharmacology and categorized as
phase I and phase II reactions. These reactions are important in
the metabolism of medicinal drugs and toxins. This evolutionary
history also applies for humans which enables us to metabolize a
large number of xenobiotics.
In phase I, a lipophilic SM is made more hydrophilic by intro-
ducing hydroxyl groups. This reaction is catalyzed by CYP and
CYP1A1, CYP1A2, CYP3A4, and CYP2D6 are the most important
enzymes. Furthermore, theseCYP can cleaveN -methyl,O-methyl,
or methylene groups in order to obtain a more hydrophilic or bet-
ter accessible substrate (Guengerich, 2001). In the human genome,
about 57 active CYP genes are known (Ingelman-Sundberg and
Gomez, 2010). A substantial polymorphism of CYPs exists which
enables them to metabolize a wide range of xenobiotics. The regu-
lation of the corresponding genes is only partly known. The genes
encoding these enzymes, which occur in intestinal epithelia and
in the liver, are inducible by SM that have entered the body. In
phase II, the hydroxylated xenobiotics are conjugated with polar
molecules, such as glutathione, sulfate, or glucuronic acid. These
conjugates are eliminated via the kidneys and urine. That means,
on exposure to lipophilic SM, genes which encode these enzymes
are often induced and that activation can inactivate the toxins.
Several SM carry methylenedioxy groups on their phenolic rings,
such as in the isoquinoline alkaloids berberine and hydrastine,
which are assumed to be inhibitors of CYP (Wink, 2007). Alka-
loids which can inhibit CYP have been summarized by Wink
(2007).
Resistance mechanisms in bacterial pathogens are even more
evident because several pathogens already have evolved resis-
tance against medicinally used antibiotics. The main mechanisms
include:
• Direct inactivation of the antibiotic, e.g., by cleavage of the
beta-lactam ring of penicillin by beta-lactams or acetylation,
methylation of other antibiotics
• Target site modiﬁcation: molecular change of the target mole-
cule (proteins, rRNA) in such a way that the antibiotic cannot
bind any longer
• Bypass or alteration of metabolic pathways in cases where an
antibiotic blocks a pathway (e.g., as for sulfonamides)
• Prevention of drug uptake
• Export out of the cell by ABC transporters so that the intra-
cellular concentration of an antibiotic (e.g., tetracycline) are
reduced. In Bacteria, this is one of several factors responsible
for multidrug resistance (MDR).
ABC TRANSPORTER
Resistance against defense chemicals can be obtained through the
expression of ABC transporters that are present in most cells and
organisms. They are especially active in epithelia of intestinal, liver,
kidney, and endothelia (Twentyman and Bleehen, 1991; Nielsen
and Skovsgaard, 1992; Nooter and Stoter, 1996; Steinbach et al.,
2002; You and Morris, 2007).
Three types of ABC transporters have been studied in detail:
1. P-glycoprotein (P-gp;molecular weight 170 kD) or MDR1 pro-
tein (multiple drug resistance protein) was the ﬁrst clonedABC
transporter. It is encoded by theABCB1 gene. P-gp is composed
of two similar moieties and each half contains one transmem-
brane and one ATP-binding domain. P-gp is an efﬂux pump
directed to the gut lumen. The substrate molecules bind to
transmembrane domains and then are exported to extracellu-
lar space, driven by the energy of ATP hydrolysis. A wide range
of lipophilic chemotherapeutical agents, such as anthracenes,
anthracyclines, epipodophyllotoxins, taxanes, and Vinca alka-
loids, which can enter tumor cells by free diffusion, are sub-
strates of P-gp and can be extruded by the transporter (Loo
and Clarke, 2005).
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2. Multiple resistance-associated protein 1 (MRP1; 190 kD) is
encoded by the ABCC1 gene. MRP1 transports drugs conju-
gated to glutathione (GSH), and also unmodiﬁed therapeutics
in the presence of GSH (van der Kolk et al., 1999). MRP1
is structurally similar to P-gp, and can expel anthracene-
dione, anthracycline, epipodophyllotoxin, Vinca alkaloids, etc.
(Wijnholds et al., 2000).
3. Breast cancer resistance protein (BCRP; 72 kD) is the prod-
uct of the ABCG2 gene. It has one transmembrane domain
and one ATP-binding domain and only functions after dimer-
ization. BCRP confers resistance to doxorubicin, camptothecin,
and mitoxantrone (Ambudkar et al., 1999; Schinkel and Jonker,
2003; Mao and Unadkat, 2005; Krishnamurthy and Schuetz,
2006).
Breast cancer resistance protein and P-gp are highly expressed at
the apical membrane of blood–brain barrier (BBB), placenta, liver,
intestine, and other organs (Schinkel and Jonker, 2003). These
ATP-driven transporters can pump lipophilic compounds out of
the cell, either back to the gut lumen or into the blood system,
thus reducing the intracellular concentration of potentially toxic
compounds.
ATP-binding cassette transporters are also important at the
BBB. The BBB only allows the entry of small lipophilic sub-
stances by passive diffusion. However, the uptake of lipophilic
compounds in the brain is relatively low due to the high activ-
ity of P-gp, MRP, and organic anion transporting polypeptides
(OATPs). These transporters catalyze a rapid efﬂux of lipophilic
xenobiotics from the CNS (Elsinga et al., 2004; Mahringer and
Fricker, 2010).
Multidrug resistance was discovered during chemotherapy of
cancer patients who developed resistance against a cytotoxic drug.
It transpired that the tumor cells were able to pump out the
lipophilic alkaloids (such asVinca alkaloids, taxanes,and anthracy-
cline derivatives) at almost the same speed as theywere entering the
tumor cells. Activated cells became resistant to vincristine but also
to several other lipophilic drugs. Thismeans that a cross-resistance
or MDR had occurred. As a consequence, a major obstacle to the
successful chemotherapy of tumors is MDR. Upon exposure to
xenobiotics MDR genes can become upregulated. Overexpressed
ABC transporters (P-gp, MRP1, or BCRP) can mediate resistance
of tumor cells against a variety of anticancer drugs (Schinkel and
Jonker, 2003). This phenomenon is called MDR, which is one of
the most important reasons of chemotherapy failure (Gottesman,
2002).
Several of human protozoal parasites (Plasmodium, Leishma-
nia, Trypanosoma) can develop resistance against prophylactic
and therapeutic agents, such as quinolines, naphthoquinones,
sesquiterpene lactones, and others. The underlying mechanism
includes membrane glycoproteins that are orthologous to human
P-gp. These ABC transporters can also be induced and activated.
ATP-binding cassette transporters are also present in bacteria
and fungi in which they confer resistance to antibiotics and fungi-
cidal compounds (Steffens et al., 1996). A medicinally important
issue is the increasing resistance of bacteria toward antibiotics,
and ABC transporters can be involved in bacterial MDR (besides
othermechanisms discussed above).Apparently,ABC transporters
are an old invention of nature, which occur from E. coli to
Homo sapiens.
OVERCOMING RESISTANCE CAUSED BY ABC
TRANSPORTERS
Multidrug resistance reversal agents are also called chemosen-
sitizers or modulators. They can inhibit the efﬂux activity of
transporters and other relevantMDR targets (see above); in conse-
quence they can potentiate cytotoxicity, and are therefore impor-
tant alternatives to overcomeMDR (Watanabe et al., 1995;Dantzig
et al., 1996; Robert and Jarry, 2003).
Multi-resistant tumor cells frequently express different ABC
transporters simultaneously, e.g., P-gp, MRP1, BCRP, and others
(Annereau et al., 2004; Gillet et al., 2004). Because the substrate
spectra of ABC transporters only partly overlap, co-expression
of transporters might produce more diverse resistance proﬁles
than those of any one member alone. Thus broad-spectrum rever-
sal agents are needed and some compounds exhibit this prop-
erty (Hyaﬁl et al., 1993; Maliepaard et al., 2001; Brooks et al.,
2003).
A number of natural or synthetic compounds have been dis-
covered that can inhibit P-gp and re-sensitize resistant tumor
cells in vitro (Chauffert et al., 1990; Genne et al., 1992; He and
Liu, 2002; Wink, 2007). Although these agents work successfully
in some patients, most results of clinical trials were disappoint-
ing (Solary et al., 2000; Dantzig et al., 2001). Some of these
reversal agents did not work in vivo or some had too severe
side effects. Therefore, new and better reversal agents are still
needed.
Most modulators of ABC transporters act by binding to mem-
brane transport proteins (especially P-gp, MRP1, and BCRP) as
competitive inhibitors, or by indirect mechanisms related to phos-
phorylation of the transport proteins, or the expression of the
mdr1 and mrp1 genes. Other inhibitors not only act at the level
of the transporter gene but inﬂuence their expression; for exam-
ple, the alkaloid piperine lowered the expression levels of ABCB1,
ABCC1, and ABCG2 genes which encode P-gp, MRP1, and BCRP
(Li et al., 2011b).
INHIBITORS OF ABC TRANSPORTERS FROM PLANTS
For this review we carried out a comprehensive literature research.
Table 2 summarizes the search results for SM from plants, which
can serve as ABC transporter substrates and might be useful
in strategies to reverse drug resistance in cancer cells, fungi,
and parasites. Compounds affecting other resistance mechanisms,
which are important and which were discussed above, were not
considered in this review.
Lipophilic SM, such as monoterpenes, diterpenes, triterpenes
(including saponins), steroids (including cardiac glycosides), and
tetraterpenes (carotenoids; Table 2) function as substrates for P-gp
in cancer cells. The ABC transporter from fungi, AtrB (Andrade
et al., 2000), or the NorA efﬂux pump in Staphylococcus aureus can
also be affected (Smith et al., 2007). Because of their lipophilicity,
these terpenoids most likely are substrates for P-gp and other ABC
transporter. If administered as a chemosensitizer in combination
with a cytotoxic agent they function as inhibitors competing for
binding to the active side of the transporters.
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Table 2 | Secondary metabolites from plants that can inhibit P-gp, MRP1, BCRP, bacterial, and fungal ABC transporters.
Natural product Occurrence Activities Reference
TERPENOIDS
Monoterpenes
Citronellal, citronellol Zanthoxylum piperitum
(Rutaceae)




2 (biphasic action) Najar et al. (2010)
Jatrophane diterpene
polyesters
Euphorbia serrulata, E. esula, E.
salicifolia, E. peplus
(Euphorbiaceae)
3 in mouse lymphoma cells Hohmann et al. (2002)
Latilagascene A, latilagascene













Reverses MDR in resistant
Mycobacterium tuberculosis strains
Rojas et al. (2006)
Betulinic acid, pomolic acid Licania tomentosa,
Chrysobalanus icaco,
(Chrysobalanaceae)
3 in leukemia cells Fernandes et al. (2003)
Limonin, deacetylnomilin Citrus jambhiri, Citrus pyriformis,
Phellodendron amurense
(Rutaceae)
6 Min et al. (2007), El-Readi et al. (2010)




3 in cancer cells; 7 Kurimoto et al. (2011a,b)
Euscaphic acid, tormentic
acid, 2 α -acetyl tormentic
acid, 3β-acetyl tormentic acid
Cecropia lyratiloba (Moraceae) 3 in leukemia cell line Rocha Gda et al. (2007)










1 in MDR cancer cells Min et al. (2007)
Phytolacca saponins N-1–N-5 Phytolacca americana
(Phytolaccaceae)
3 in 2780 AD cells Wang et al. (2008)
Sinocalycanchinensin E Sinocalycanthus chinensis
(Calycanthaceae)
Enhances colchicine-induced
cytotoxicity in MDR KB cells
Kashiwada et al. (2011)
β-Amyrin, uvaol, oleanolic acid Carpobrotus edulis (Aizoaceae) 3 in mouse lymphoma cell line and
Gram-positive bacteria
Martins et al. (2010), Ordway et al.
(2003)
Steroids





8 Madureira et al. (2004)
Digoxin, digitoxin Digitalis spp. (Plantaginaceae) 2 de Lannoy and Silverman (1992),
Cavet et al. (1996)
Ginsenoside Rc, ginsenosides
Rd, parishin C
Panax spp. (Araliaceae) 4 in lymphoma cells Berek et al. (2001)
Methylprototribestin Tribulus terrestris
(Zygophyllaceae)
4 (doxorubicin) Ivanova et al. (2009)
Protopanaxatriol (ginsenoside) Panax ginseng (Araliaceae) 2, 4 in AML-2/D100 cells Choi et al. (2003)
(Continued)
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Table 2 | Continued
Natural product Occurrence Activities Reference
Stigmasterol,
β-sitosterol-O-glucoside
Citrus jambhiri, Citrus pyriformis
(Rutaceae)
1 in Caco2 and leukemia cells El-Readi et al. (2010)






Daucus carota spp. sativus
(Apiaceae)
1, 9 Molnar et al. (2004), Kars et al. (2008),
Gyemant et al. (2006)
PHENOLICS
Phenyl propanoids
Chlorogenic acid Coffea arabica (Rubiaceae) and
many plants
1 Najar et al. (2010)
Curcumin,
tetrahydrocurcumin
Curcuma longa (Zingiberaceae) 1, 5 Zhou et al. (2004), Limtrakul et al.
(2007), Hou et al. (2008), Lu et al. (2012)
Flavonoids, catechins, chalcones, xanthones, stilbenes, anthocyanins, and related polyphenols
Acacetin Several families 1, 10 in human erythrocytes and
breast cancer cells
Wesolowska et al. (2009)
Afrormosin, robinin,
amorphigenin
Several Fabaceae 1, 10 Gyemant et al. (2005)
Ampelopsin Hovenia dulcis (Rhamnaceae) 1, 5 in K562/ADR cells Ye et al. (2009)
Apigenin, Several plants 1, 4, 9, 10 in MES-SA/DX5 cells;
substrate for multidrug transporter
in Plasmodium falciparum
Zhang et al. (2004), Leslie et al. (2001),
Perez-Victoria et al. (1999),Wesolowska
et al. (2009), Angelini et al. (2010)
Baicalein Scutellaria baicalensis
(Lamiaceae)
Substrate for Yorlp and Pdr5p
transporters in yeast
Saccharomyces cerevisiae
Kolaczkowski et al. (1998)
Biochanin A Several families 1, 9 Chung et al. (2005), Zhang et al. (2004)
Calodenin B, dihydrocalodenin
B, and other dimeric
proanthocyanidins
Ochna macrocalyx (Ochnaceae) Inhibit MDR in Staphylococcus
aureus (RN4220, XU212, and
SA-1199-B)
Tang et al. (2003)
Chrysin Several species 1, 2 (biphasic action), 9 Molnár et al. (2008), Gyemant et al.
(2005), Zhou et al. (2004), Zhang et al.




Artemisia annua L. (Asteraceae) Synergistic inhibition of MDR in
Staphylococcus aureus





Glycine max L. Merr. (Fabaceae),
Aronia melanocarpa L.
(Rosaceae)
1 Molnár et al. (2008)
Daidzein Several species of Fabaceae 1, 9, 10 Chung et al. (2005), Zhang et al. (2004),





9 (in vitro and in vivo) An et al. (2011)
Diosmin Citrus spp. (Rutaceae) 2 Yoo et al. (2007)
Ellagic acid, tannic acid Several species Inhibit an efﬂux pump in
Acinetobacter baumannii and
enhances antibiotic activity







1 in MCF-7/Adr and mouse
lymphoma cell line; 9, 10; 3 in
Gram-positive bacteria
Martins et al. (2010), Zhang et al. (2004),
Zhu et al. (2001), Gyemant et al. (2005),
Mei et al. (2004), Wei et al. (2003)
(Continued)
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Table 2 | Continued
Natural product Occurrence Activities Reference
Fisetin Several species 2, 9 in breast cancer cells; 4 in
MES-SA/DX5 cells; substrate for
Yorlp transporters in yeast
Saccharomyces cerevisiae
Chung et al. (2005), Kolaczkowski
et al. (1998), Angelini et al. (2010)
Formononetin and other
isoﬂavones
Several species of Fabaceae 1, 2, 10 Molnár et al. (2008), Gyemant et al.
(2005)
Galangin Several plant families 2 (biphasic action); 10 Zhou et al. (2004), Critchﬁeld et al.
(1994), de Wet et al. (2001)
Genistein and derivatives Several species of Fabaceae 1, 2, 9, 10 Zhang et al. (2004), Taur and
Rodriguez-Proteau (2008), Leslie




Citrus jambhiri, Citrus pyriformis
(Rutaceae)
1, 9 El-Readi et al. (2010), Zhang et al.
(2004), Ofer et al. (2005)
Icariin Epimedium grandiﬂorum
(Berberidaceae)
1, 5 Liu et al. (2009)
Isobavachalcone Dorstenia barteri (Moraceae) Inhibits efﬂux pump in
Gram-negative bacteria




Several plants 2 (biphasic action); 1 and OCT, 9, 10 Zhou et al. (2004), Zhang et al.
(2004), deWet et al. (2001), Gyemant
et al. (2005)















1, 9, 10; substrate for MDR1 in
Plasmodium falciparum
Chung et al. (2005), Zhang et al.
(2004), Ofer et al. (2006), Leslie
et al. (2001), Perez-Victoria et al.
(1999), de Castro et al. (2007, 2008),




Several species 1 in MDR KB-C2 cells Kitagawa et al. (2007)
Phloretin, phloridzin Several species 1, 9 Molnár et al. (2008), Zhang and Mor-
ris (2003), Zhang et al. (2004), Gye-
mant et al. (2005)
Plagiochin E Marchantia polymorpha
(Marchantiaceae)
Reverses the efﬂux pump in
Candida albicans






Several species 1 and OCT in MDR cancer cells; 9,
10; substrate for Yorlp in yeast
Saccharomyces cerevisiae
substrate for MDR1 in Plasmodium
falciparum.
Scambia et al. (1994), Kolaczkowski
et al. (1998), Shapiro and Ling (1997),
Conseil et al. (1998), Cooray et al.
(2004), Ofer et al. (2005), Ohtani
et al. (2007), Leslie et al. (2001),
Zhang et al. (2004)
Resveratrol Several plants 7, 9 Cooray et al. (2004)
Rotenone Derris spp.,Tephrosia spp.,
Lonchocarpus spp. (Fabaceae)
1 Molnár et al. (2008), Gyemant et al.
(2005)
Rutin Several species 1 and OCT; substrate of MDR in
Plasmodium falciparum
Ofer et al. (2005, 2006), Foster et al.
(2001), Perez-Victoria et al. (1999)
(Continued)
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Table 2 | Continued
Natural product Occurrence Activities Reference
Silymarin (isosilybin,
silychristin, silydianin, silybin)
Silybum marianum (Asteraceae) 1, 4, 5, 9 in cancer cells Zhou et al. (2004), Agarwal et al.
(2006), Zhang and Morris (2003),
Zhang et al. (2004), Trompier et al.
(2003)
Tiliroside Platanus orientalis (Platanaceae),
Herissantia tiubae (Malvaceae)
5; inhibits (NorA) efﬂux protein in
Staphylococcus aureus
Falcao-Silva et al. (2009)
Tricin Sasa borealis (Gramineae) 3 in adriamycin-resistant
MCF-7/ADR cells







3 in MCF-7/ADR and Bel-7402/5-Fu
cells
Li et al. (2011a)
3,5,4′-Trimethoxy-trans-
stilbene
Dalea versicolor (Fabaceae) Enhances the antimicrobial effect of
berberine against NorA S. aureus
mutant strain










Inhibits efﬂux pump in
Gram-negative bacteria
Kuete et al. (2010)
Emodin Rheum palmatum
(Polygonaceae)
2; synergistic antimicrobial effect
with ampicillin or oxacillin in MRSA
Lee et al. (2010), Cui et al. (2008)
Rhein Rheum palmatum
(Polygonaceae)
2, 4 Cui et al. (2008), van Gorkom et al.
(2002)
Lignans
Syringaresinol Sasa borealis (Gramineae) 1 in adriamycin-resistant
MCF-7/ADR cells





Citrus hybrids (Rutaceae) 1 de Castro et al. (2007, 2008)
Alkaloids
Acronycine Bauerella australiana 2 Dorr et al. (1989)
Arborinine, evoxanthine Ruta graveolens (Rutaceae) 1, 5 in cancer cells Rethy et al. (2008)
Berbamine Berberis sp. (Berberidaceae) 2 in BBB and in Caco2 cells He and Liu (2002)
Berberine Hydrastis canadensis
(Ranunculaceae)
1, 2, 2 in BBB; 8 (bacteria) 2 in
vascular smooth muscle cells
(VSMCs)
Severina et al. (2001), He and Liu




Substrate for ABC2 transporter in
Botrytis cinerea; for PMR5 in
Penicillium digitatum, AtrBp in
Aspergillus nidulans; 11
Mattern et al. (1993), Lee et al.
(2005), Nakaune et al. (2002),











aureus (MRSA); and a MDR strain
of S. aureus
O’Donnell and Gibbons (2007)
Capsaicin Capsicum frutescens
(Solanaceae)
2, 4 Okura et al. (2010)
Catharanthine 2, 4 (vinblastine) in CEM/VLB1K
cells
Beck et al. (1988), Zamora et al.
(1988)
(Continued)
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Table 2 | Continued
Natural product Occurrence Activities Reference
Cepharanthine Stephania cepharantha
(Menispermaceae)
4 (doxorubicin and vincristine) Ikeda et al. (2005), Katsui et al.
(2004), Nakajima et al. (2004)
Chelerythrine Zanthoxylum clava-herculis
(Rutaceae)
Reversal of drug resistance in methicillin-
resistant Staphylococcus aureus (MRSA)
Gibbons et al. (2003)
Cinchonine, hydrocinchonine,
quinidine
Cinchona pubescens (Rubiaceae) 4 Solary et al. (2000), Genne et al.
(1994), Lee et al. (2011)
Colcemid, colchicine Colchicum autumnale
(Colchicaceae)
2 Elsinga et al. (2004)
Conoduramine Peschiera laeta (Apocynaceae) 2, 4 in KB cells You et al. (1994)
Coptisine Several species of
Ranunculaceae; Berberidaceae
2 in vascular smooth muscle cells
(VSMCs)
Suzuki et al. (2010)
8-Oxocoptisine Coptis japonica (Ranunculaceae) 1 in MES-SA/DX5 and HCT15 cells Min et al. (2006b)
Coronaridine, heyneanine
dippinine B and C
Tabernanthe iboga
(Apocynaceae)
4 in vincristine-resistant KB cells Kam et al. (2004)
Cycleanine Synclisia scabrida
(Menispermaceae)
6 in MCF-7/Adr and KBv200 cells Tian and Pan (1997)
Cyclopamine Veratrum spp. (Melanthiaceae) 1, 3 Lavie et al. (2001)
Dauriporphine Sinomenium acutum
(Menispermaceae)
1 in MES-SA/DX5 and HCT15 cells Min et al. (2006a)
Emetine Psychotria ipecacuanha
(Rubiaceae)
2, 11 Möller et al. (2006)
Ergotamine Claviceps purpurea
(Clavicipitaceae)
1 in MDR cells Yasuda et al. (2002)
Fangchinoline Stephania tetrandra
(Menispermaceae)
Reduces resistance to paclitaxel and
actinomycin D in HCT15 cells
Choi et al. (1998), Wang et al. (2005)
Galanthamine Galanthus nivalis
(Amaryllidaceae)
1 at the BBB Namanja et al. (2009)
Gamma-fagarine Phellodendron amurense
(Rutaceae)
1 MDR cancer cells Min et al. (2007)
Glaucine Glaucium ﬂavum (Papaveraceae) 1, 2 Ma and Wink (2009)
Harmine Peganum harmala
(Zygophyllaceae)





2, 11 Zhou et al. (1995), Efferth et al. (2003)
Hydrastine Hydrastis canadensis
(Ranunculaceae)
2 Etheridge et al. (2007)
Ibogaine Tabernanthe iboga
(Apocynaceae)
5, 9 Tournier et al. (2010)
Indole-3-carbinol Many species of Brassicaceae Downregulation of upregulated P-gp;
dietary adjuvant in MDR cancer treatment
Arora and Shukla (2003)
Insularine, insulanoline Antizoma miersiana
(Menispermaceae)
9 in MCF-7/Adr and KBv200 cells Tian and Pan (1997)
Kopsamine, pleiocarpine,
lahadinine A, kopsiﬂorine
Kopsia dasyrachis (Apocynaceae) 4 Kam et al. (1998)






Inhibitor of NorA MDR pump in
Staphylococcus aureus




Mirabilis jalapa (Nyctaginaceae) Inhibits growth of Staphylococcus aureus
overexpressing the multidrug efﬂux
transporter NorA
Michalet et al. (2007)
(Continued)
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1 in MDR cancer cells Min et al. (2007)
Paclitaxel Taxus spp. (Taxaceae) 2 Distefano et al. (1997)
Palmatine Several species of
Ranunculaceae; Berberidaceae
2 in vascular smooth muscle cells
(VSMCs); 8 (bacteria)
Severina et al. (2001), Suzuki et al.
(2010)
Piperine Piper nigrum (Piperaceae) 1, 2, 3, 9 in cancer cells; inhibition
of overexpressed mycobacterial
putative efﬂux protein (Rv1258c)
Han et al. (2008), Bhardwaj et al.
(2002), Li et al. (2011b), Sharma et al.
(2010)




3 of vinblastine; induces MDR1 and
p-gp expression
Bhat et al. (1995)
Reserpine Rauvolﬁa serpentina
(Apocynaceae)
8 in bacteria; 3 in
methicillin-resistant Staphylococcus
aureus (MRSA) strains (NorA MDR
pump); 2; 3 of vinblastine in
CEM/VLB1K cells
Beck et al. (1988), Gibbons and Udo
(2000), Markham et al. (1999)
Roemerine Annona senegalensis
(Annonaceae)
2; 4 You et al. (1995)
Rutaecarpine Evodia rutaecarpa (Rutaceae) 6 in p-gp overexpressing
CEM/ADR5000 cells
Lee et al. (1995), Adams et al. (2007)
Sanguinarine Sanguinaria canadensis
(Papaveraceae)




Stemona aphylla and S. burkillii
(Stemonaceae)
P-gp modulator, enhance the
cytotoxicity of vinblastine,
paclitaxel, and doxorubicin in KB-V1
cells
Chanmahasathien et al. (2011)
Tetrandrine Stephania tetrandra
(Menispermaceae)
1; reduces resistance to paclitaxel
and actinomycin D in HCT15 cells; 4
in MDR mice; 6 (in vitro and in vivo);
4in cancer patients treated with
doxorubicin, etoposide, and
cytarabine
Choi et al. (1998), Xu et al. (2006),
Zhu et al. (2005), Fu et al. (2002,
2004)
Thaliblastine Thalictrum spp. (Ranunculaceae) Reverses MDR by decreasing the
overexpression of P-gp in
MCF-7/Adr cells
Chen and Waxman (1995), Chen
et al. (1993, 1996)
Tomatidine Solanum lycopersicum
(Solanaceae)






1 and 3 in L5178 MDR mouse
lymphoma cells
Zupko et al. (2009)
Vasicine acetate, 2-acetyl
benzylamine
Adhatoda vasica. (Acanthaceae) Inhibit Mycobacterium tuberculosis
and a MDR strain
Ignacimuthu and Shanmugam (2010)
Veralosinine, veranigrine Veratrum lobelianum, Veratrum
nigrum (Melanthiaceae)
1 and 3 against doxorubicin Ivanova et al. (2011)
Vincristine, Vinblastine Catharanthus roseus
(Apocynaceae)
2; 2 in BBB; 11 He and Liu (2002), Hu et al. (1995)
Vindoline 2; reversal of vinblastine resistance
in a MDR human leukemic cell line
and CEM/VLB1K cells
Beck et al. (1988)
(Continued)
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Natural product Occurrence Activities Reference
Voacamine Peschiera laeta, Peschiera
fuchsiaefolia (Apocynaceae)
1, 2; 2 in BBB; reversal of
vinblastine; and doxorubicin
resistance in MDR cancer cells by
binding to P-glycoprotein




Reversal of vinblastine resistance in
a MDR human leukemic cell line
and CEM/VLB 100 cells
Zamora et al. (1988), Bhat et al.
(1995)
Activities: 1: inhibits p-gp; 2: p-gp substrate; 3: reversal of MDR; 4: reversal of p-gp mediated MDR; 5: inhibition of MDR1 gene. 6: p-gp modulation in cancer cells;
7: induction of apoptosis; 8: substrate for ABC transporter; 9: blocks BCRP and increases in mitoxantrone accumulation; 10: MRP1 inhibitor; 11: induction of MDR
overexpression.
Among the structurally heterogenous group of alkaloids, a
large number of the more lipophilic substances from the classes
of isoquinoline, protoberberine, quinoline, indole, monoterpene
indole, and steroidal alkaloids (Table 2) can serve as substrates
whereas the more polar alkaloids with a tropane, quinolizidine,
piperidine, and pyrrolizidine skeleton do not bind to ABC trans-
porters (Wink, 2007). Similar to the situation of terpenoids, the
active alkaloids probably function as competitive inhibitors of P-
gp and BCRP in cancer cells, and NorA in bacteria and fungi
(Table 2).
It is remarkable on the ﬁrst sight that also quite a large
number of more polar phenolic SM (phenolic acids, ﬂavonoids,
catechins, chalcones, xanthones, stilbenes, anthocyanins, tan-
nins, anthraquinones, and naphthoquinones) inhibit P-gp,MRP1,
BCRP, and OATP in cancer cells with MDR. Some of them can
reverse MDR when given in combination with cytotoxic agents
(Table 2). Bacteria and fungi appear to be sensitive as well (Guz
et al., 2001; Falcao-Silva et al., 2009). Some of these pheno-
lics are lipophilic enough to be competitive inhibitors of ABC
transporters.
Polyphenols are exciting tethering compounds of proteins.
They can effectively interact directly with proteins by forming
hydrogen and ionic bonds with amino acid side chains. They
can thus interfere with the 3D structure of proteins (conforma-
tion) and inhibit their activities (details in Wink, 2008b; Wink
and Schimmer, 2010). We speculate therefore, that the inhibition
seen in polyphenols is caused by a direct binding and complex
formation (not necessarily the active side) of ABC transporters.
Since many polyphenols have no or very low toxicity (e.g., many
of them are ingredients of our food, such as ﬂavonoids or tannins),
they might be excellent candidates as reversal agents, both in
chemotherapy and in agriculture.
We have focused on ABC transporters in this review. But as
mentioned above, resistance can be due to other mechanisms
as well and is often multifactorial. Faria et al. (2011) and Kim
et al. (2007, 2010) have successfully employed thymol (a pheno-
lic monoterpene), salicyl aldehyde, and the alkaloid berberine to
enhance the activity of fungicides in Candida, Aspergillus, Penicil-
lium, and Cryptococcus. These experimental data can be regarded
as a proof of concept that plant secondary products can be interest-
ing candidates for chemosensitization (even if they not interfere
with ABC transporters) of pathogenic fungi in agriculture and
food technology to improve the fungicidal activity of certain
fungicides.
CONCLUSION
This review summarizes the evidence that selected SM of plants
can be interesting candidates to inhibit ABC transporters in
MDR cancer cells or to chemosensitize pathogenic fungi and
other microbes for treatment with antimicrobial agents. Whereas
lipophilic terpenoids and alkaloids appear to be substrates of P-gp,
MRP1, or BCRP and thus competitive inhibitors, the more polar
phenolic compounds (ﬂavonoids, tannins, quinones) can bind to
the transporter proteins and inhibit their activity by disturbing
protein conformation. A combination of a cytotoxic agent, antibi-
otic, or fungicide with a natural chemosensitizer (not necessarily
an inhibitor of ABC transporters) might provide an interesting
strategy to overcome MDR in cancer patients and to improve
antibiotic or antifungal efﬁcacy in medicine, agriculture, or food
industry.
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